Article Details
Retrieved on: 2022-04-19 11:19:28
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca said: “The DESTINY-Lung01 trial confirmed the HER2 mutation as an actionable ...
Article found on: www.bdtonline.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here